Reports related to this article:
Project(s): View 3 related projects in PECWeb
Plant(s): View 3 related plants in PECWeb
Released January 19, 2016 | SUGAR LAND
en
Reported by Annette Kreuger, Industrial Info Resources (Sugar Land, Texas)--The Pharma-Bio Industry is not usually the first thing that comes to mind when one mentions Texas. But beyond the smoke stacks of the hundreds of the state's chemical processing plants and refineries are a surprising number of life science plants and research centers.
Click on the image on the right for a table detailing Texas life science projects.
A recent survey taken from Industrial Info's PECWEB Direct revealed 62 active projects with a cumulative total investment value (TIV) of $3.73 billion in various stages of development. Some are already under construction, while others are in preliminary planning. Of this total, 33 projects worth $2.19 billion have a future kick-off date.
These projects top every city planner's list because of the typically high wages and future expansion prospects they offer.
For years, many have wondered why the Houston area has not leaped to the top in commercial life science activity. Home to what is arguably the world's top medical center, the area is a veritable brain trust when it comes to answering the medical needs of human beings. Nevertheless, it has been a struggle to become the Boston of the South. Perhaps it is the preconceived notion of Texas as only a location for heavy process industry, and not a good match for the "clean" manufacturing and research of pharmaceutical and biotech companies. That is a fallacy.
The projects range in size from a $1 million regularly scheduled maintenance program at the DSM Nutritionals plant in Freeport, Texas to the astounding $750 million Texas Medical Center's TMC3 Innovation Campus plan in Houston.
What Texas has to offer is a lot of empty space and a pro-business environment. The intellectual capital is present and accounted for, as well as a plethora of able workers. It is going to take a little more effort, but there are signs the tide may be slowly turning.
Industry giant Allergan PLC (NYSE:AGN) (Dublin, Ireland) decided long ago before the Actavis merger that Waco, Texas, was a great fit for its massive specialty pharmaceutical manufacturing plant that is set on a 12-acre site. The latest in a long line of expansions at the campus is the $100 million project now under way to add what is referred to as "Sterile 7 Building." With the bulk of that total going to equipment, the project will be completed in phases throughout the next several years, with DPR Construction (Austin, Texas) overseeing construction.
Novartis' (NYSE:NVS) (Basel, Switzerland) Alcon division is considering a $100 million Ophthalmic Solutions (Eye) Alcon Sterile Products Expansion (ASPEX) Campus Sterile Filling & Packaging Plant Addition in Fort Worth, Texas. A new sterile filling and packaging building would be added on the 100-acre Alcon campus to support the existing 72,000-square-foot ASPEX facility. Current production capacity is approximately 12 million to 16 million units per month of aseptic eye and ear solutions.
Industrial Info Resources (IIR), with global headquarters in Sugar Land, Texas, five offices in North America and 10 international offices, is the leading provider of global market intelligence specializing in the industrial process, heavy manufacturing and energy markets. Industrial Info's quality-assurance philosophy, the Living Forward Reporting Principle, provides up-to-the-minute intelligence on what's happening now, while constantly keeping track of future opportunities. Follow IIR on: Facebook - Twitter - LinkedIn. For more information on our coverage, send inquiries to info@industrialinfo.com or visit us online at http://www.industrialinfo.com/.
Click on the image on the right for a table detailing Texas life science projects.A recent survey taken from Industrial Info's PECWEB Direct revealed 62 active projects with a cumulative total investment value (TIV) of $3.73 billion in various stages of development. Some are already under construction, while others are in preliminary planning. Of this total, 33 projects worth $2.19 billion have a future kick-off date.
These projects top every city planner's list because of the typically high wages and future expansion prospects they offer.
For years, many have wondered why the Houston area has not leaped to the top in commercial life science activity. Home to what is arguably the world's top medical center, the area is a veritable brain trust when it comes to answering the medical needs of human beings. Nevertheless, it has been a struggle to become the Boston of the South. Perhaps it is the preconceived notion of Texas as only a location for heavy process industry, and not a good match for the "clean" manufacturing and research of pharmaceutical and biotech companies. That is a fallacy.
The projects range in size from a $1 million regularly scheduled maintenance program at the DSM Nutritionals plant in Freeport, Texas to the astounding $750 million Texas Medical Center's TMC3 Innovation Campus plan in Houston.
What Texas has to offer is a lot of empty space and a pro-business environment. The intellectual capital is present and accounted for, as well as a plethora of able workers. It is going to take a little more effort, but there are signs the tide may be slowly turning.
Industry giant Allergan PLC (NYSE:AGN) (Dublin, Ireland) decided long ago before the Actavis merger that Waco, Texas, was a great fit for its massive specialty pharmaceutical manufacturing plant that is set on a 12-acre site. The latest in a long line of expansions at the campus is the $100 million project now under way to add what is referred to as "Sterile 7 Building." With the bulk of that total going to equipment, the project will be completed in phases throughout the next several years, with DPR Construction (Austin, Texas) overseeing construction.
Novartis' (NYSE:NVS) (Basel, Switzerland) Alcon division is considering a $100 million Ophthalmic Solutions (Eye) Alcon Sterile Products Expansion (ASPEX) Campus Sterile Filling & Packaging Plant Addition in Fort Worth, Texas. A new sterile filling and packaging building would be added on the 100-acre Alcon campus to support the existing 72,000-square-foot ASPEX facility. Current production capacity is approximately 12 million to 16 million units per month of aseptic eye and ear solutions.
Industrial Info Resources (IIR), with global headquarters in Sugar Land, Texas, five offices in North America and 10 international offices, is the leading provider of global market intelligence specializing in the industrial process, heavy manufacturing and energy markets. Industrial Info's quality-assurance philosophy, the Living Forward Reporting Principle, provides up-to-the-minute intelligence on what's happening now, while constantly keeping track of future opportunities. Follow IIR on: Facebook - Twitter - LinkedIn. For more information on our coverage, send inquiries to info@industrialinfo.com or visit us online at http://www.industrialinfo.com/.
